-Reuters
nicycive Therapeutics Received Decision To Grant European Patent Number EP3848040 Titled “LANTHANUM DIOXYCARBONATE AND USE (FOR TREATING PATIENTS WITH HYPERPHOSPHATEMIA)”
https://twitter.com/PatentGrants/status/1635726713815719936
Related Posts
JP Morgan Maintains Overweight on Apple, Lowers Price Target to $180
JP Morgan analyst Samik Chatterjee maintains Apple (NASDAQ:AAPL) with a Overweight and lowers the price target from $190 to $180.
Blue Origin Successfully Completes Journey To Space, Virgin Galactic Shares Tumble
Amazon.com, Inc. (NASDAQ: AMZN) founder Jeff Bezos successfully reached space on Tuesday morning, becoming the second high-profile billionaire to make the journey aboard a private commercial flight this month.
